Evidence map›Paper›PMID 40760028›Full record

ArticleBMC medical imaging2025

Combined nomogram for differentiating adrenal pheochromocytoma from large-diameter lipid-poor adenoma using multiphase CT radiomics and clinico-radiological features.

Zujuan Shan, Xinzhang Zhang, Yiwen Zhang, Shuailong Wang, Junfeng Wang, Xin Shi, Lin Li, Zhenhui Li, Liuyang Yang, Hao Liu and 3 more

Abstract read
In one paragraph

Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zujuan Shan *Department of Urology, Honghe Hospital Affiliated to Kunming Medical University (South Yunnan Central Hospital of Yunnan Province), No. 1, Xiyuan Road, Gejiu City, Honghe, Yunnan, 661017, China.
Xinzhang Zhang *The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, 650100, China.
Yiwen Zhang *The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, 650100, China.
Shuailong WangThe Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, 650100, China.
Junfeng WangThe Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, 650100, China.
Xin ShiSecond Affiliated Hospital of Kunming Medical University, No. 374, Dianmian Avenue, Wuhua District, Kunming, Yunnan, 650106, China.
Lin LiDepartment of Urology, Honghe Autonomous Prefecture 3rd Hospital, Honghe, Yunnan, 661100, China.
Zhenhui LiThe Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, Yunnan, 650118, China.
Liuyang YangThe Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, Yunnan, 650118, China.
Hao LiuDepartment of Research & Development, Yizhun Medical AI Co. Ltd., Beijing, 100086, China.
Wenliang LiSecond Affiliated Hospital of Kunming Medical University, No. 374, Dianmian Avenue, Wuhua District, Kunming, Yunnan, 650106, China. liwenliang@kmmu.edu.cn.
Junfeng YangThe Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, 650100, China. yjfkmmc@163.com.
Liansheng YangDepartment of Urology, Honghe Hospital Affiliated to Kunming Medical University (South Yunnan Central Hospital of Yunnan Province), No. 1, Xiyuan Road, Gejiu City, Honghe, Yunnan, 661017, China. hhzyykyk@163.com.

Funding

Kunming Medical University Joint Special Program for Basic Research XDYC-YLWS-2023-0071Yunnan Talent Support Plan 202301AY070001-052
6 · The paper itself

Abstract

BACKGROUND AND

objectiveAdrenal incidentalomas (AIs) are predominantly adrenal adenomas (80%), with a smaller proportion (7%) being pheochromocytomas(PHEO). Adenomas are typically non-functional tumors managed through observation or medication, with some cases requiring surgical removal, which is generally safe. In contrast, PHEO secrete catecholamines, causing severe blood pressure fluctuations, making surgical resection the only treatment option. Without adequate preoperative preparation, perioperative mortality risk is significantly high.A specialized adrenal CT scanning protocol is recommended to differentiate between these tumor types. However, distinguishing patients with similar washout characteristics remains challenging, and concerns about efficiency, cost, and risk limit its feasibility. Recently, radiomics has demonstrated efficacy in identifying molecular-level differences in tumor cells, including adrenal tumors. This study develops a combined nomogram model, integrating key clinical-radiological and radiomic features from multiphase CT, to enhance accuracy in distinguishing pheochromocytoma from large-diameter lipid-poor adrenal adenoma (LP-AA).

methodsA retrospective analysis was conducted on 202 patients with pathologically confirmed adrenal PHEO and large-diameter LP-AA from three tertiary care centers. Key clinico-radiological and radiomics features were selected to construct models: a clinico-radiological model, a radiomics model, and a combined nomogram model for predicting these two tumor types. Model performance and robustness were evaluated using external validation, calibration curve analysis, machine learning techniques, and Delong's test. Additionally, the Hosmer-Lemeshow test, decision curve analysis, and five-fold cross-validation were employed to assess the clinical translational potential of the combined nomogram model.

resultsAll models demonstrated high diagnostic performance, with AUC values exceeding 0.8 across all cohorts, confirming their reliability. The combined nomogram model exhibited the highest diagnostic accuracy, with AUC values of 0.994, 0.979, and 0.945 for the training, validation, and external test cohorts, respectively. Notably, the unenhanced combined nomogram model was not significantly inferior to the three-phase combined nomogram model (p > 0.05 in the validation and test cohorts; p = 0.049 in the training cohort).

conclusionsThe combined nomogram model reliably distinguishes between PHEO and LP-AA, shows strong clinical translational potential, and may reduce the need for contrast-enhanced CT scans. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

AdenomaAdrenal Gland NeoplasmsNomogramsPheochromocytomaTomography, X-Ray ComputedAdultAgedDiagnosis, DifferentialFemaleHumansMaleMiddle AgedRadiomicsRetrospective StudiesClinico-radiological factorsLipid-poor adenomaPheochromocytomaRadiomics

Identifiers

PMID40760028
PMCPMC12323233

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.